Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 45HER2-positive Breast Cancer 8Carcinoma, Non-Small-Cell Lung 5Breast Diseases 3Brain Neoplasms 3Advanced Breast Cancer 3Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Salivary Gland Neoplasms 1Rare Tumour 1Rare Tumor 1Pathologic Complete Response 1Non Small Cell Lung 1Neoplasm Metastasis 1Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1Metastatic Breast Cancer in the Brain 1Lung Neoplasms 1HER2-positive Metastatic Breast Cancer 1HER2-positive Early Breast Cancer 1HER2+ Early or Locally Advanced Breast Cancer 1HER2 Positive Metastatic Breast Cancer 1HER2 Positive Breast Cancer 1HER2 Insertion Mutation Positive Advanced NSCLC 1Estrogen Receptor-positive Breast Cancer 1Esophageal Squamous Cell Carcinoma 1Digestive System Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Breast Cancer Invasive 1

Interventions

pyrotinib 1pertuzumab 1atezolizumab 1Trastuzumab 1Capecitabine 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × HER2-positive Metastatic Breast Cancer × pyrotinib × Clear all
NCT05042791 2024-02-09

A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases

Jiangxi Provincial Cancer Hospital

Phase 2 Unknown
362 enrolled
Breast

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡